Combined Use of Thyroid Hormone and ECT

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Electroconvulsive therapy (ECT) can cause neurocognitive deficits like confusion and memory impairment.
• Interactions between neurocognition, the hypothalamic-pituitary-thyroid axis, mood, and ECT are documented.
• Preclinical studies suggest triiodothyronine (T3) may counteract amnesia and speed antidepressant effects of electroconvulsive shock (ECS) in animals.

Purpose of the Study:

• To investigate the potential of triiodothyronine (T3) to mitigate neurocognitive side effects of electroconvulsive therapy (ECT).
• To explore the impact of T3 augmentation on the clinical efficacy of ECT.

Main Methods:

• Review of laboratory and clinical research on ECT, neurocognition, and the thyroid axis.
• Analysis of preclinical data on T3 administration during electroconvulsive shock (ECS).
• Evaluation of clinical findings from combined T3 and ECT treatments.

Main Results:

• Exogenous T3 administration in animal models protected against electroconvulsive shock (ECS)-induced amnesia.
• T3 administration accelerated the antidepressant effects of ECS in preclinical studies.
• Clinical data indicate that combined T3 and ECT treatment enhances ECT's efficacy and reduces cognitive side effects.

Conclusions:

• Triiodothyronine (T3) shows potential as an adjunctive treatment to electroconvulsive therapy (ECT).
• T3 may improve the therapeutic ratio of ECT by enhancing efficacy and reducing cognitive impairment.
• Further clinical investigation into T3 augmentation for ECT is warranted.